## Express Mail No. EV 577 672 077 US

Express transfer				
INFORMATION	Attorney Docket	BERK-032		
DISCLOSURE STATEMENT	First Named Inventor	KEASLING, JAY D.		
	Application Number	10/573,796		
	Confirmation No.	7712		
	Filing Date	September 29, 2004 (International)		
Address to:	Group Art Unit	1636		
Mail Stop PCT Commissioner for Patents	Examiner Name			
P.O. Box 1450 Alexandria, VA 22313-1450	Title: "METHODS FOR IDENTIFYING A BIOSYNTI PATHWAY GENE PRODUCT"			

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C.§102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. BERK-032 may be charged thereon.

Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLI

Paula A. Borden Registration No. 42,344

Date: Mar. 8, 2007

BOZICEVIC, FIELD & FRANCIS LLP 1900 University Avenue, Suite 200 East Palo Alto, California 94303 Telephone: (650) 327-3400

Facsimile: (650) 327-3231

PTO/SB/08a (09-06)

Approved for use through 03/31/2007. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE and to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
·				Application Number	10/573,796
1	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	September 29, 2004 (international)
ŀ				First Named Inventor	KEASLING, JAY D.
017(12.11.21(1.21(1.21(1.21(1.21(1.21(1.2				Art Unit	1636
(Use as many sheets as necessary)			v)	Examiner Name	
Sheet	1	of	2	Attorney Docket Number	BERK-032

			U.S. PATENT	DOCUMENTS	
Examiner Initials'	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 7,172,886	02-06-2007	KEASLING et al.	
		US-			
	-	118-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials'	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁰
muais	NO.	Country Code Number Kind Code (in Nown)	- WILLIAM - 1			
			<del> </del>			
						-
						├-
						_
						<u> </u>

Cumminas		Date	
Examiner	/Nancy Vogel/		
Signature	/Nancy Vogel/	Considered	06/10/2000
Signature	, , ,		99/10/2000

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. A Kind of document by the appropriate symbols as indicated on the document under WIPO Standard \$1.16 if possible. Applicant is to place a check mark here if English language Translation is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b (09-06)

Approved for use through 03/31/2007, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known		
				Application Number	10/573,796	
INFORMATION DISCLOSURE				Filing Date	September 29, 2004 (international)	
STATEMENT BY APPLICANT				First Named Inventor	KEASLING, JAY D.	
			CANI	Art Unit	1636	
	(Use as many sheets a	s necessa	rv)	Examiner Name		
Sheet	2	of	2	Attorney Docket Number	BERK-032	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BACK and CHAPPELL, "Identifying functional domains within terpene cyclases using a domain- swapping strategy" Prac. Natl. Acad. Sci. (1996), vol. 93, pp. 8841-8845	
		MARTIN et al., "Engineering a mevalonate pathway in <i>Escherichia coli</i> for production of terpenoids" Nature Biotechnology (2003), vol. 21, no. 7, pp. 796-802	
		TRAPP and CROTEAU, "Genomic Organization of Plant Terpene Synthases and Molecular Evolutionary Implications" Genetics (2001), vol. 158, pp. 811-831	
		WANG and OHNUMA (2000) "Isopronyl diphosphate syntheses" Biochinna et Biophysa Acta, vol. 1323, pp. 33-48	

Examiner Signature	/Nancy Vogel/	Date Considered	06/17/2009

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

\*Applicants unique clusten designation unrother optionals.\* Applicant is to place a check mark here if English language Translation is attached.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Apparents a unique citation onesignation instructs (operating). Apparents in to present a vision, a more vision in Citation in support in the citation of information is required by 2 of CPH 127 and 134. The alternative instruction is not included by 2 of CPH 127 and 134. The alternative instruction is not included by a complete vision in application. Confidentially one of the complete in 134 of CPH 14. The collection is estimated to take 2 for complete in USPT 0 operation in the confidential instruction i